Key Technologies and Compliance Points for the Research and Development of In Vitro Diagnostic Biomedical Reagents

I. Relationship Between In Vitro Diagnostic Reagents and Biomedical Reagents

In vitro diagnostic (IVD) reagents are reagent combinations used for in vitro detection of target substances in human samples, and they constitute a category of biomedical reagents with relatively strong regulatory attributes. Their development involves not only basic disciplines such as molecular biology, immunology, and biochemistry, but also engineering aspects such as process scale-up, stability studies, and quality control. Since IVD reagents may ultimately be used for disease screening, auxiliary diagnosis, or treatment monitoring, the requirements for consistency and reliability of product performance are higher than those for general research reagents.

From the perspective of product forms, IVD reagents may include nucleic acid amplification reagents, antigen-antibody detection reagents, biochemical detection reagents, cell or microbial identification reagents, etc. Conducting design within the framework of legal compliance and quality management helps R&D teams translate laboratory results into stable, reproducibly manufactured products.

II. Screening and Supply Management of Core Raw Materials

Core raw materials are the foundation of IVD reagent performance, commonly including antibodies, antigens, enzymes, primers and probes, nucleotides, substrates, and standards. When screening raw materials, attention is usually paid to purity, activity, affinity, specificity, and lot-to-lot consistency. For key raw materials, supplier evaluation and sample testing processes can be established to avoid supply risks caused by a single source.

In molecular diagnostic reagents, enzymes and probes are important factors affecting amplification efficiency and specificity. In immunodiagnostic reagents, the selection of antibody pairs, labeling methods, and solid-phase carriers all need to be determined through comprehensive experiments. After raw materials arrive, small-sample testing and long-term retention samples should be conducted to ensure that subsequent lots can meet product performance requirements.

III. Formulation and Process Development

Formulation development is the process of combining selected raw materials into a usable reaction system. Common work includes optimization of buffer systems, screening of ionic strength and pH, selection of blocking agents, and ratios of protective agents and preservatives. Process development involves the order of preparation, mixing methods, filtration sterilization, lyophilization or liquid filling, etc. During this stage, key parameters should be recorded and traceable experimental records should be established.

Platforms such as chemiluminescence, enzyme-linked immunosorbent assay, and quantitative fluorescence PCR have different requirements for reagent state and reaction conditions; therefore, formulation development needs to be validated in combination with the actual platform. Lyophilization processes have relatively strict control requirements for temperature curves, vacuum levels, and residual moisture, and generally require multiple rounds of testing to determine.

IV. Main Indicators for Analytical Performance Evaluation

Performance evaluation is an essential part of IVD reagent development. Common analytical performance indicators include sensitivity, specificity, precision, linear range, limit of detection, interference testing, and stability, etc. Sensitivity and specificity are directly related to the accuracy of test results; precision reflects intra-assay and inter-assay variation; the linear range determines the applicable scope of quantitative detection.

Interference testing can evaluate the effects of common endogenous or exogenous substances on detection signals, such as hemoglobin, bilirubin, lipemia, or commonly used drugs. R&D personnel should design reasonable sample groups and replicate numbers to avoid one-sided conclusions drawn from individual outliers. Analytical performance evaluation data are also important content in product registration dossiers.

V. Stability Studies and Shelf-Life Setting

Stability studies of IVD reagents usually include long-term stability, open-vial stability, transport stability, and reconstitution stability, etc. Stability studies should be conducted under conditions close to actual storage and transport, observing trends over time in appearance, performance indicators, and quality control sample results. Shelf-life setting needs to be based on data rather than simply referring to similar products.

Temperature-sensitive reagents should be monitored for performance changes under high-temperature or freeze-thaw conditions. For lyophilized reagents, the standing time after reconstitution is also part of stability. During the study, temperature and humidity, lots, and testing time points should be recorded for subsequent analysis.

VI. Quality Management System and Production Control

IVD reagent R&D and production require the establishment of a quality management system covering design and development, procurement, production, testing, sales, and after-sales service. Design and development control should specify requirements for inputs, outputs, reviews, verification, and validation. Production control includes clean environment management, process parameter monitoring, in-process testing, and finished product testing, etc.

Key processes should be validated to ensure continuous output of products meeting quality requirements. Change management is also crucial. When changes occur in raw material suppliers, formulations, or production processes, the possible impact on product performance should be evaluated, and revalidation should be carried out when necessary.

VII. Registration and Regulatory Pathways

In China, IVD reagents are subject to classified management according to risk level. Class I products are generally filed, while Class II and Class III products usually require registration. During the registration process, product technical requirements, analytical performance evaluation materials, stability study materials, clinical evaluation materials, etc. need to be submitted.